Document is current
Any future updates will be listed below
-
Authors
Sharma, Kumar https://orcid.org/0000-0002-7550-8525
Hansen, Jens https://orcid.org/0000-0002-1362-6534
Susztak, Katalin https://orcid.org/0000-0002-1005-3726
Eberlin, Livia
Anderton, Christopher R. https://orcid.org/0000-0002-6170-1033
Alexandrov, Theodore https://orcid.org/0000-0001-9464-6125
Iyengar, Ravi https://orcid.org/0000-0002-7814-0180
- License Information
-
More Information
Article History
Accepted: 1 September 2025
First Online: 9 October 2025
Competing interests
: T.A. is an inventor of a patent on the single-cell metabolomics technology SpaceM. T.A. is a co-founder, shareholder and board member for DeepCyte, Inc. as well as a co-founder, shareholder and board member for Metacloud, Inc. L.E. is an inventor in patents related to the MSPen technology owned by the University of Texas at Austin that were licensed to MS Pen Technologies, Inc. L.E. is a co-founder, shareholder, chief scientific officer and board member for MSPen Technologies. L.E. is an inventor in patents related to DESI-MS imaging technology, which were licensed by Purdue University to Waters Corporation. The laboratory of K. Susztak receives research support from Novo Nordisk, Novartis, Gilead, Regeneron, Genentech, Boehringer, GSK, AZ, KKC and Calico. K. Susztak serves on the advisory board of Pfizer and Otsuka and has equity in TarnaTx. K. Sharma has served as consultant for Cara Therapeutics, Inc. and has equity in SygnaMap. R.I., J.H. and C.R.A. report no competing interests.
